Single-dose psilocybin treatment for major depressive disorder.

A randomized clinical trial of 104 adults, including a placebo group (I wonder if those people quickly figured out which group they were in?). In any case, the results of the psilocybin group look strong. “The primary outcome was change in central rater–assessed Montgomery-Asberg Depression Rating Scale (MADRS) score (range, 0-60; higher scores indicate more severe depression) from baseline to day 43.” The average for the intervention was -12.3, vs -2.3 for the control. ~ learn more